Table 5. Factors associated with survival in unresectable HCC patients treated with TACE+sorafenib.

	Univariate		Multivariate
	HR (95% CI)	p-value	HR (95% CI)	p-value
Tumor size (cm)
<5	Ref		Ref
≥5	2.09(1.52-2.85)	<0.001	1.54(1.11-2.14)	0.01
PVTT
No	Ref		Ref
Yes	1.78(1.29-2.47)	0.001	1.1(0.78-1.56)	0.583
Extrahepatic metastasis
No	Ref		Ref
Yes	1.54(1.05-2.27)	0.027	1.08(0.72-1.61)	0.707
Duration of sorafenib treatment	0.89(0.87-0.91)	<0.001	0.9(0.87-0.92)	<0.001

PVTT, portal vein tumor thrombus

No significant affect in survival were found in age, gender, α-fetoprotein, Child-Pugh, tumor number, and Eastern Cooperative Oncology Group status.